פרוסטין אי2 ג'ל וגינלי 1 מג ישראל - עברית - Ministry of Health

פרוסטין אי2 ג'ל וגינלי 1 מג

pfizer pfe pharmaceuticals israel ltd - dinoprostone - ג'ל - dinoprostone 0.033 %w/w - dinoprostone - dinoprostone - for labour induction in term and near term pregnant women who have favorable induction features and who have a singleton pregnancy with vertex presentation

פרוסטין אי2 ג'ל וגינלי 2 מג ישראל - עברית - Ministry of Health

פרוסטין אי2 ג'ל וגינלי 2 מג

pfizer pfe pharmaceuticals israel ltd - dinoprostone - ג'ל - dinoprostone 0.066 %w/w - dinoprostone - dinoprostone - for labour induction in term and near term pregnant women who have favorable induction features and who have a singleton pregnancy with vertex presentation

פרוסטין  10 מגמל E2 ישראל - עברית - Ministry of Health

פרוסטין 10 מגמל e2

pfizer pfe pharmaceuticals israel ltd - dinoprostone - תמיסה להזרקה - dinoprostone 10 mg/ml - dinoprostone - dinoprostone - therapeutic termination of pregnancy, missed abortion.

פרופס ישראל - עברית - Ministry of Health

פרופס

ferring pharmaceuticals ltd - dinoprostone - התקן תוך נרתיקי - dinoprostone 10 mg - dinoprostone - dinoprostone - initiation and/or continuation of cervical ripening in patients at term, from 38th week of gestation, with bishop score of 6 or less.

פרוסטין 3 מג E2 ישראל - עברית - Ministry of Health

פרוסטין 3 מג e2

pfizer pfe pharmaceuticals israel ltd - dinoprostone - טבליות וגינליות - dinoprostone 3 mg - dinoprostone

פרפדיל ג'ל ישראל - עברית - Ministry of Health

פרפדיל ג'ל

pfizer pharmaceuticals israel ltd - dinoprostone 0.5 mg / 3 g - gel - dinoprostone - rippening of cervix prior to induction of labour

צייטוטק 200 מקג טבליות ישראל - עברית - Ministry of Health

צייטוטק 200 מקג טבליות

pfizer pfe pharmaceuticals israel ltd - misoprostol - טבליה - misoprostol 200 mcg - misoprostol - misoprostol - for the treatment of duodenal and gastric ulcer.treatment and prevention nsaid induced ulcers lesions, erosions, while nsaid therapy continues.use in conjunction with mifepristone subject to the approval of a committee for the termination of pregnancy according to the israeli penal law 1977.first-trimester pregnancy failure: use is intended for emptying the uterus in states of first trimester pregnancy failure, including: presentation of a pregnancy sac in the uterus with no fetal echo, missed abortion (until week 11+6 and a fetus 40 mm in length) or incomplete abortion. the preparation is to be used after location of the sac in the uterus has been proved and the diagnosis of pregnancy failure is certain. the preparation can be used for this purpose in an ambulatory setting. the dosage and route of administration will be similar to the use of cytotec in pregnancy termination after using mifegyne. informed consent and medical surveillance are required.softening and dilation of the cervix for performing intraut

מיפג'ין ישראל - עברית - Ministry of Health

מיפג'ין

a. lapidot pharmaceuticals, ltd - mifepristone - טבליה - mifepristone 200 mg - mifepristone - mifepristone - medical alternative to uterine suction for termination of intra-utrerine pregnancy: - up to and no later than 49 days of amenorrhea (seven weeks) - in sequential use with a prostaglandin analogue misoprostol 400 mcg per os administered 36 to 48 hours after mifegyne intake. under these conditions the association of mifepristone and prostaglandins leads to a success rate of about 95 per cent of the cases. preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reason (beyond the first trimester). softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.

מיסודיל ישראל - עברית - Ministry of Health

מיסודיל

ferring pharmaceuticals ltd - misoprostol - misoprostol 200 mcg - misoprostol

ארטרוטק 75 ישראל - עברית - Ministry of Health

ארטרוטק 75

pfizer pharmaceuticals israel ltd - diclofenac sodium 75 mg; misoprostol 200 mcg - tablets - diclofenac - for patients requiring longterm anti-inflammatory treatment, in such circumstances where there is a high risk of developing hemorrhage or ulcer i.e. patients with a peptic ulcer or past gastric bleeding, patients with cardiovascular disease, patients over 65 and smokers.